<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01350271</url>
  </required_header>
  <id_info>
    <org_study_id>P39/04/2010</org_study_id>
    <secondary_id>Ragama ERC</secondary_id>
    <nct_id>NCT01350271</nct_id>
  </id_info>
  <brief_title>Comparative Efficacy of Different Mebendazole Polymorphs in the Treatment of Soil-transmitted Helminth Infections</brief_title>
  <official_title>Comparative Efficacy of Different Mebendazole Polymorphs in the Treatment of Soil-transmitted Helminth Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kelaniya</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kelaniya</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mebendazole tablets which are produced by most pharmaceutical manufacturers, including the
      State Pharmaceutical Manufacturing Corporation (SPMC) of Sri Lanka, contain a mixture of
      polymorphs A and C. However, there is some evidence to show that mebendazole polymorph C is
      the only form effective against the soil-transmitted helminths. This protocol describes a
      stratified, randomized, placebo-controlled trial that examined the efficacy of different
      mebendazole polymorphs produced by the SPMC in the treatment of hookworm infections.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mebendazole has three polymorphic forms, identified as A, B and C. All of them are in accord
      with the US Pharmacopeia specifications (USP XXI) but they have distinct physiochemical
      characteristics (Himmelreich et al, 1977) and different therapeutic activities in
      experimentally infected mice with Trichinella spiralis infections (Rodriguez-Caabeiro et al,
      1987). The original mebendazole tablets which were used to treat human infections had more
      than 90% of polymorph C (Van den Bossche et al, 1982), but most pharmacopeias currently do
      not specify the proportion of polymorph C that a tablet of mebendazole should contain, and
      the assay specified for measurement of the active ingredient measures all polymorphs
      together. There is some evidence to show that unlike polymorph C, polymorph A is ineffective
      in the treatment of hookworm and whipworm infections (Charoenlarp et al, 1993). The State
      Pharmaceutical Manufacturing Corporation of Sri Lanka produces both 500 mg and 100 mg tablets
      of mebendazole according to specifications laid down in the US Pharmacopeia. These tablets
      contain a mixture of polymorphs A and C. It is possible that increasing the content of
      mebendazole polymorph C in single dose tablets may improve cure rates and egg reduction
      rates, especially against hookworm and whipworm infections, where much variation in efficacy
      has been observed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cure Rate</measure>
    <time_frame>Two weeks</time_frame>
    <description>Cure rate={(Number positive pretreatment - Number positive posttreatment)÷(Number positive pretreatment)}×100</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Faecal Egg Count Reduction 1 (FECR1)</measure>
    <time_frame>Two weeks</time_frame>
    <description>FECR1= {[(Arithmetic mean of pretreatment egg counts)-(arithmetic mean of posttreatment egg counts)]÷(arithmetic mean of pretreatment egg counts)}×100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Faecal Egg Count Reduction 2 (FECR2)</measure>
    <time_frame>Two weeks</time_frame>
    <description>FECR2=〈Arithmetic mean {[(pretreatment egg count)-(posttreatment egg count)]÷(pretreatment egg count)}〉×100</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">214</enrollment>
  <condition>Necator Americanus Infection</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets produced by the State Pharmaceutical Manufacturing Corporation of Sri Lanka</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mebendazole polymorph A and C 500 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mebendazole tablets produced by the State Pharmaceutical Manufacturing Corporation of Sri Lanka, containing 500mg of mebendazole as a 50:50 mixture of Polymorphs A and C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mebendazole polymorph C 500 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mebendazole tablets manufactured by the State Pharmaceutical Manufacturing Corporation of Sri Lanka, containing 500mg dose of mebendazole as Polymorph C alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mebendazole polymorph A and C 500 mg</intervention_name>
    <description>Mebendazole tablets produced by the State Pharmaceutical Manufacturing Corporation of Sri Lanka, containing 500mg of mebendazole as a 50:50 mixture of Polymorphs A and C</description>
    <arm_group_label>Mebendazole polymorph A and C 500 mg</arm_group_label>
    <other_name>Lot FG10M01</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mebendazole polymorph C</intervention_name>
    <description>Mebendazole tablets manufactured by the State Pharmaceutical Manufacturing Corporation of Sri Lanka, containing 500mg dose of mebendazole as Polymorph C alone</description>
    <arm_group_label>Mebendazole polymorph C 500 mg</arm_group_label>
    <other_name>Lot FG10H01</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets produced by the State Pharmaceutical Manufacturing Corporation of Sri Lanka</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Necator americanus infection, as determined by examination of a single faecal smear,
             alone or with Ascaris lumbricoides or Trichuris trichiura

        Exclusion Criteria:

          -  Children below the age of 2 years

          -  Pregnant women

          -  Individuals with diarrhea on day of treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nilanthi R de Silva, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine, University of Kelaniya, Sri Lanka</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Agalawatta Plantations PLC</name>
      <address>
        <city>Nivitigala</city>
        <state>Sabragamuwa</state>
        <country>Sri Lanka</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lellopitiya Estate, Hapugastenne Plantations PLC</name>
      <address>
        <city>Ratnapura</city>
        <state>Sabragamuwa</state>
        <country>Sri Lanka</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sri Lanka</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2011</study_first_submitted>
  <study_first_submitted_qc>May 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2011</study_first_posted>
  <results_first_submitted>August 23, 2011</results_first_submitted>
  <results_first_submitted_qc>April 18, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 22, 2013</results_first_posted>
  <last_update_submitted>April 18, 2013</last_update_submitted>
  <last_update_submitted_qc>April 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Kelaniya</investigator_affiliation>
    <investigator_full_name>N R de Silva</investigator_full_name>
    <investigator_title>Professor of Parasitology</investigator_title>
  </responsible_party>
  <keyword>Hookworm</keyword>
  <keyword>Necator americanus</keyword>
  <keyword>Mebendazole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Helminthiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mebendazole</mesh_term>
    <mesh_term>Piperazine</mesh_term>
    <mesh_term>Piperazine citrate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>In order to identify those with hookworm infections, all individuals living in 219 households, in 8 estate divisions in Ratnapura District known to have a high prevalence of hookworm, were recruited to the study after obtaining their written, informed consent. Each person was requested to provide one faecal sample.</recruitment_details>
      <pre_assignment_details>Infants below the age of 2 years, pregnant women, and those with diarrhoea on the day of recruitment were excluded from the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>70 were allocated to this arm and 49 were followed up in the post treatment.</description>
        </group>
        <group group_id="P2">
          <title>Mebendazole Polymorph A and C 500 mg</title>
          <description>70 were allocated and 53 were followed up in the post treatment.</description>
        </group>
        <group group_id="P3">
          <title>Mebendazole Polymorph C 500 mg</title>
          <description>74 were allocated and 48 were followed up in the post treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="70"/>
                <participants group_id="P3" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="53"/>
                <participants group_id="P3" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All those found positive for hookworm infection, from among the population screened at baseline</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Hookworm positive participants randomized to placebo</description>
        </group>
        <group group_id="B2">
          <title>Mebendazole Polymorph A and C 500 mg</title>
          <description>Hookworm positive participants randomized to a single dose of Mebendazole polymorph A and C 500 mg</description>
        </group>
        <group group_id="B3">
          <title>Mebendazole Polymorph C 500 mg</title>
          <description>Hookworm positive participants randomized to a single dose of Mebendazole polymorph C 500 mg</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="70"/>
            <count group_id="B2" value="70"/>
            <count group_id="B3" value="74"/>
            <count group_id="B4" value="214"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34" spread="18"/>
                    <measurement group_id="B2" value="36" spread="19"/>
                    <measurement group_id="B3" value="32" spread="18"/>
                    <measurement group_id="B4" value="34" spread="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Sri Lanka</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cure Rate</title>
        <description>Cure rate={(Number positive pretreatment - Number positive posttreatment)÷(Number positive pretreatment)}×100</description>
        <time_frame>Two weeks</time_frame>
        <population>All participants who were hookworm positive at baseline, and who provided a faecal sample for examination at follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Hookworm infected individual randomized to placebo</description>
          </group>
          <group group_id="O2">
            <title>Mebendazole Polymorph A and C 500 mg</title>
            <description>Hookworm infected individuals randomized to a single dose of Mebendazole polymorph A and C 500 mg</description>
          </group>
          <group group_id="O3">
            <title>Mebendazole Polymorph C 500 mg</title>
            <description>Hookworm infected individuals randomized to a single dose of Mebendazole polymorph C 500 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Cure Rate</title>
          <description>Cure rate={(Number positive pretreatment - Number positive posttreatment)÷(Number positive pretreatment)}×100</description>
          <population>All participants who were hookworm positive at baseline, and who provided a faecal sample for examination at follow up.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3"/>
                    <measurement group_id="O2" value="28.3"/>
                    <measurement group_id="O3" value="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Faecal Egg Count Reduction 1 (FECR1)</title>
        <description>FECR1= {[(Arithmetic mean of pretreatment egg counts)-(arithmetic mean of posttreatment egg counts)]÷(arithmetic mean of pretreatment egg counts)}×100</description>
        <time_frame>Two weeks</time_frame>
        <population>All participants who were hookworm positive at baseline, and who provided a faecal sample for examination at follow-up, were included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Hookworm positive participants randomized to placebo</description>
          </group>
          <group group_id="O2">
            <title>Mebendazole Polymorph A and C 500 mg</title>
            <description>Hookworm positive participants randomized to a single dose of Mebendazole polymorph A and C 500 mg</description>
          </group>
          <group group_id="O3">
            <title>Mebendazole Polymorph C 500 mg</title>
            <description>Hookworm positive participants randomized to a single dose Mebendazole polymorph C 500 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Faecal Egg Count Reduction 1 (FECR1)</title>
          <description>FECR1= {[(Arithmetic mean of pretreatment egg counts)-(arithmetic mean of posttreatment egg counts)]÷(arithmetic mean of pretreatment egg counts)}×100</description>
          <population>All participants who were hookworm positive at baseline, and who provided a faecal sample for examination at follow-up, were included in the analysis</population>
          <units>percentage of eggs excreted</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.6"/>
                    <measurement group_id="O2" value="86.1"/>
                    <measurement group_id="O3" value="84.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Faecal Egg Count Reduction 2 (FECR2)</title>
        <description>FECR2=〈Arithmetic mean {[(pretreatment egg count)-(posttreatment egg count)]÷(pretreatment egg count)}〉×100</description>
        <time_frame>Two weeks</time_frame>
        <population>All participants who were hookworm positive at baseline, and who provided a faecal sample for examination at follow up were included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Hookworm positive participants randomized to placebo</description>
          </group>
          <group group_id="O2">
            <title>Mebendazole Polymorph A and C 500 mg</title>
            <description>Hookworm positive participants randomized to a single dose of Mebendazole polymorph A and C 500 mg</description>
          </group>
          <group group_id="O3">
            <title>Mebendazole Polymorph C 500 mg</title>
            <description>Hookworm positive participants randomized to a single dose Mebendazole polymorph C 500 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Faecal Egg Count Reduction 2 (FECR2)</title>
          <description>FECR2=〈Arithmetic mean {[(pretreatment egg count)-(posttreatment egg count)]÷(pretreatment egg count)}〉×100</description>
          <population>All participants who were hookworm positive at baseline, and who provided a faecal sample for examination at follow up were included in the analysis</population>
          <units>percentage of eggs excreted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-108.1" spread="557.5"/>
                    <measurement group_id="O2" value="66.2" spread="42.5"/>
                    <measurement group_id="O3" value="49.8" spread="82.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Hookworm positive participants randomized to placebo</description>
        </group>
        <group group_id="E2">
          <title>Mebendazole Polymorph A and C 500 mg</title>
          <description>Hookworm positive participants randomized to a single dose of Mebendazole polymorph A and C 500 mg</description>
        </group>
        <group group_id="E3">
          <title>Mebendazole Polymorph C 500 mg</title>
          <description>Hookworm positive participants randomized to a single dose of Mebendazole polymorph C 500 mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Release after two years after completing trial</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size owing to limitation in available funds.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Balachandran Kumarendran</name_or_title>
      <organization>University of Kelaniya</organization>
      <phone>0094112961140</phone>
      <email>drbkumaran@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

